Trospium Chloride Capsule, Extended Release
Product Images NDC 71335-2931

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 71335-2931). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 01)

Chemical structure of Trospium Chloride, the active ingredient in Trospium Chloride ER 60 mg extended-release capsules by Bryant Ranch Prepack.*

FDA Label Image

Figure 1 (Image 02)

A line chart depicting plasma concentration (ng/mL) of Trospium Chloride Extended-Release Capsules 60 mg over time (hours post-dose). The graph shows concentration rising to a peak around 4 hours, then gradually decreasing up to 24 hours, with error bars indicating variability at each time point.*

FDA Label Image

Figure 2 (Image 03)

A line graph comparing average change over time between placebo and Trospium Chloride Extended-Release Capsules groups. The x-axis represents time points at 0, 1, 4, and 12 weeks, and the y-axis shows average changes with standard error. Data points include statistical significance values (p-values) at weeks 1, 4, and 12. The placebo group is represented with filled circles and a dashed line; the Trospium Chloride group with open circles and a solid line.*

FDA Label Image

Figure 3 (Image 04)

A line graph comparing average change values over time between placebo and Trospium Chloride Extended-Release Capsules, with data points at 0, 1, 4, and 12 weeks. The graph includes error bars and p-values indicating statistical significance at each measured interval.*

FDA Label Image

Figure 4 (Image 05)

A line graph comparing the average change over time between placebo and Trospium Chloride Extended-Release Capsules groups. The x-axis represents time points (0, 1, 4, and 12 weeks), and the y-axis shows the average change with standard error. Statistical significance values (p-values) are annotated at various time points, demonstrating greater change observed in the Trospium Chloride group compared to placebo.*

FDA Label Image

Figure 5 (Image 06)

A line graph comparing average change over time between placebo and Trospium Chloride Extended-Release Capsules (60 mg) groups. The x-axis represents time points (0, 1, 4, and 12), and the y-axis shows average change with standard error bars. Trospium Chloride shows greater average change at all measured points with statistical significance indicated (p<0.001).*

FDA Label Image

Label (Lbl713352931)

Label for Trospium Chloride Extended-Release Capsules 60 mg, showing NDC 71335-2931-1. The label includes usage instructions, storage conditions, and warnings to keep out of reach of children. It indicates a package size of 30 capsules unit-of-use. The labeler is Bryant Ranch Prepack and the manufacturer is Sidmak Laboratories Pvt. Ltd.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.